-
公开(公告)号：US20240360195A1
公开(公告)日：2024-10-31
申请号：US18579283
申请日：2022-07-13
Inventor： Reinhard Zeidler
IPC: C07K14/705 , A61K38/00
CPC classification number: C07K14/70503 , A61K38/00 , C07K2317/14 , C07K2317/55 , C07K2317/565
Abstract: The present invention relates to a novel dimer composed of a first Fab monomer and a second Fab monomer, each Fab monomer comprising a VH and a VL region, wherein two of such VH or VL regions are covalently linked by a disulfide bond between an additional non-naturally occurring cysteine residue at their respective N-termini.
-
公开(公告)号：US20240355416A1
公开(公告)日：2024-10-24
申请号：US18753994
申请日：2024-06-25
Applicant: Scipher Medicine Corporation
Inventor： Susan GHIASSIAN , Theodore R. MELLORS , Marc SANTOLINI , Asher AMELI , Nancy SCHOENBRUNNER , Viatcheslav R. AKMAEV , Keith J. JOHNSON
IPC: G16B20/20 , A61K38/17 , A61P19/02 , A61P37/06 , C07K16/24 , G16B40/00 , G16H10/60 , G16H20/10 , G16H50/20 , G16H50/70
CPC classification number: G16B20/20 , A61K38/1793 , A61P19/02 , A61P37/06 , C07K16/241 , G16B40/00 , G16H10/60 , G16H20/10 , G16H50/20 , G16H50/70 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/76
Abstract: Presented herein are systems and methods for developing classifiers useful for predicting response to particular treatments. For example, in some embodiments, the present disclosure provides a method of treating subjects suffering from an autoimmune disorder, the method comprising administering an alternative to anti-TNF therapy to subjects who have been determined to be non-responsive via a classifier established to distinguish between responsive and non-responsive prior subjects in a cohort who have received the anti-TNF therapy.
-
3.发明公开
公开(公告)号：US20240352132A1
公开(公告)日：2024-10-24
申请号：US18579344
申请日：2022-07-14
Inventor： Xin YE , Le SUN , Weiwei ZHANG , Weikang TAO
CPC classification number: C07K16/2863 , A61P35/00 , C07K14/4716 , A61K2039/505 , C07K2317/31 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/732 , C07K2317/76 , C07K2319/30
Abstract: An antigen-binding molecule specifically binding to HGFR and EGFR, and the pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor-related diseases.
-
公开(公告)号：US20240352102A1
公开(公告)日：2024-10-24
申请号：US18424638
申请日：2024-01-26
Applicant: The United States Government As Represented By The Department Of Veterans Affairs , University of Washington
Inventor： BRIAN C. KRAEMER , PAMELA MCMILLAN
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/565
Abstract: Disclosed herein are antibodies that bind to aggregated tau/RNA complexes. Also disclosed herein are methods for treating a taupathy, dementia, ocular pharyngeal muscular dystrophy, or inhibiting microtubule polymerization with antibodies that bind to aggregated tau/RNA complexes.
-
公开(公告)号：US12123044B2
公开(公告)日：2024-10-22
申请号：US17942774
申请日：2022-09-12
Applicant: Boehringer Ingelheim RCV GmbH & Co KG , LONZA LTD. , VALIDOGEN GBMH
Inventor： Karlheinz Grillitsch , Guenther Daum , Andreas Grutsch
CPC classification number: C12P21/02 , C07K16/00 , C12N15/67 , C12N15/815 , C07K2317/55
Abstract: The present invention is in the field of recombinant biotechnology, in particular in the field of protein expression. The invention generally relates to a method of expressing a protein of interest (POI) from a host cell. The invention relates particularly to improving a host cell's capacity to express and/or secrete a protein of interest and use of the host cell for protein expression. The invention also relates to cell culture technology, and more specifically to culturing cells to produce desired molecules for medical purposes or food products.
-
公开(公告)号：US12122849B2
公开(公告)日：2024-10-22
申请号：US18157756
申请日：2023-01-20
Applicant: SYSMEX CORPORATION
Inventor： Shingo Maeta , Atsushi Fukunaga , Reema Bajaj
CPC classification number: C07K16/40 , C07K16/00 , C07K16/26 , C07K16/32 , G16B15/20 , G16B20/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/92
Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 5th, 9th and 22nd amino acid residues of a light chain defined by Kabat method to charged amino acid residues.
-
公开(公告)号：US12122817B2
公开(公告)日：2024-10-22
申请号：US17184248
申请日：2021-02-24
Applicant: Serpentide Inc.
Inventor： Yang Wei
IPC: A61K38/26 , A61K39/395 , A61K45/06 , A61P3/10 , C07K14/605 , C07K16/28 , A61K39/00
CPC classification number: C07K14/605 , A61K38/26 , A61K39/3955 , A61K45/06 , A61P3/10 , C07K16/28 , C07K16/2869 , A61K2039/505 , C07K2317/31 , C07K2317/55 , C07K2319/30 , C07K2319/35 , C07K2319/50
Abstract: Modified glucagon-like peptide (GLP1) fusion proteins with modified GLP1 polypeptides and related methods of use are described. Aspects of the disclosure further relate to fusion proteins that are GLP1 receptor agonists with a modified GLP1 fused to a stabilizing domain such as an extra cellular domain or antibody. Fusion proteins with modified GLP1 that are useful for treating or ameliorating a symptom or indication of a blood sugar disorder such as obesity and diabetes are also provided.
-
公开(公告)号：US20240343809A1
公开(公告)日：2024-10-17
申请号：US18580389
申请日：2022-07-19
Applicant: EXCELMAB INC.
Inventor： Wenjun ZHANG , Min LIU , Wenwu TIAN , Feng LI , Yanan HUA
CPC classification number: C07K16/2827 , A61P35/00 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/52 , C07K2317/55 , C07K2317/56
Abstract: A B7-H3 antibody and a use thereof are provided. The heavy chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 6-8, and the light chain complementarity determining regions of the B7-H3 antibody include the amino acid sequences shown in SEQ ID NOs. 14-16. The B7-H3 antibody can bind to a B7-H3 antigen and/or cells expressing the B7-H3 antigen. A B7-H3×CD3 bispecific antibody is constructed by using the B7-H3 antibody.
-
9.发明公开
公开(公告)号：US20240327499A1
公开(公告)日：2024-10-03
申请号：US18749171
申请日：2024-06-20
Applicant: MuHyeon Choe
Inventor： MuHyeon Choe , YongChan Lee , JaeSeon Won
IPC: C07K16/00 , C07K14/315 , C07K16/28
CPC classification number: C07K16/00 , C07K14/315 , C07K16/2896 , C07K2317/35 , C07K2317/55 , C07K2317/624 , C07K2319/00
Abstract: The present invention relates to a method for manufacturing multimers by making repeat-chains comprising repeatedly linked affinity domains binding specifically to monomers, and by using the same to create a repeat-chain/multiple-monomer complex created from the repeat-chains and a multiple number of monomers, thereby facilitating the formation of bond bridges between the monomers in the complex to produce inter-monomeric bond bridged multimer.
The present invention relates to a super-complex prepared by cross-binding between repeat-chain/multiple-monomer complexes, and a method for amplifying the effect of monomer through the formation of the said super-complex. Particularly, the repeat-chain/multiple-monomer complex is prepared by containing repeat-chains of binding domain having binding specificity to monomers as active ingredients, and then the super-complex is prepared by cross-binding between such complexes.
-
公开(公告)号：US20240318176A1
公开(公告)日：2024-09-26
申请号：US18577374
申请日：2022-07-08
Applicant: Dyne Therapeutics, Inc.
Inventor： Cody A. Desjardins , Kim Tang , James McSwiggen , Romesh R. Subramanian , Timothy Weeden , Mohammed T. Qatanani , Brendan Quinn , John Najim
IPC: C12N15/113 , A61K39/00 , A61K47/68 , C07K16/28
CPC classification number: C12N15/113 , A61K47/6807 , A61K47/6849 , C07K16/2881 , A61K2039/505 , C07K2317/55 , C12N2310/11 , C12N2310/3233 , C12N2310/3513 , C12N2320/32 , C12N2320/33
Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
